Description
Longeveron Inc. (“Longeveron”) is a leading clinical stage biotechnology company developing cell therapies for chronic aging-related diseases and other life-threatening conditions, for which there are no approved treatments. With its Initial Public Offering, the management is in a comfortable position to complete the current ongoing trials and to initiate around four additional Phase 2 clinical trials, which may subsequently lead to commercialization and a huge spike in revenues. During the first quarter of 2021, clinical trial revenue which has comprised of the Bahamas Registry Trial was negatively impacted by the COVID-19 travel restrictions as participants continue to have concerns with respect to for international travel but this is expected to turnaround given the gradual recovery of the economy. Moreover, the management has completed its 10 patient multi-center open-label Phase 1 clinical trial, and is inspecting Phase 1 top-line results in the second quarter of this year. Overall, we believe that given its strong pipeline, its solid cash position, and its revenue generation potential, Longeveron is definitely one stock that deserves a “Buy” rating at the current levels.
⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures
Want unlimited access to our reports? Purchase our $99 annual subscription!
